Eli Lilly squares up to Novo Nordisk on obesity market
![Photo: MIKE SEGAR/REUTERS / X90033](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13731358.ece/ALTERNATES/schema-16_9/doc7jojxhmsz0g11hns92qd.jpg)
Brand new peer-reviewed data on Eli Lilly’s candidate tirzepatide has set the stage for a battle within the obesity market. Novo Nordisk vs Eli Lilly. Tirzepatide vs semaglutide. The US vs Denmark.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Zealand Pharma obesity drug continues to phase II
For subscribers
Wegovy celebrates first birthday with subdued cheers
For subscribers